KORU Medical Systems (KRMD) Projected to Post Earnings on Wednesday

KORU Medical Systems (NASDAQ:KRMD) is anticipated to announce its earnings results after the market closes on Wednesday, March 12th. Analysts expect the company to announce earnings of ($0.04) per share and revenue of $8.89 million for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

KORU Medical Systems Trading Down 5.7 %

NASDAQ:KRMD opened at $2.98 on Tuesday. KORU Medical Systems has a 1 year low of $2.04 and a 1 year high of $5.05. The stock has a market capitalization of $136.59 million, a price-to-earnings ratio of -11.92 and a beta of 0.74. The stock has a fifty day moving average price of $4.01 and a two-hundred day moving average price of $3.39. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.37 and a current ratio of 2.99.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the company. Piper Sandler reissued a “neutral” rating and set a $4.50 price target on shares of KORU Medical Systems in a research report on Friday, February 14th. Craig Hallum raised their target price on KORU Medical Systems from $5.00 to $6.00 and gave the company a “buy” rating in a research note on Friday, January 17th. Canaccord Genuity Group upped their target price on KORU Medical Systems from $3.00 to $4.00 and gave the company a “buy” rating in a report on Thursday, November 14th. Finally, Lake Street Capital increased their price objective on KORU Medical Systems from $4.00 to $5.00 and gave the stock a “buy” rating in a research note on Tuesday, January 14th. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $4.70.

About KORU Medical Systems

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria.